Click here to read an edited transcript of a mult-disciplinary expert roundtable discussion in which surgeons, pharmacists, anesthesiologists and pain experts discuss insights and best practices for managing peri-operative pain and optimizing patient care.
Chad Brummett, MD Associate Professor, Anesthesiology, Director, Anesthesia Clinical Research, Director, Division of Pain Research, Michigan Medicine Back & Pain Center Ann Arbor, MI
PARTICIPANTS
Andrew C. Eppstein, MD Assistant Professor of Clinical Surgery, Indiana University School of Medicine Chief of General Surgery, Richard L. Roudebush VA Medical Center Indianapolis, IN
Nicholas Giori MD, PhD Professor of Orthopedic Surgery, Stanford University Chief of Orthopedic Surgery, VA Palo Alto Health Care System Palo Alto, CA
Georgine Lamvu, MD, MHP Professor in Obstetrics and Gynecology, University of Central Florida College of Medicine Division of Surgery, Gynecology Section Orlando VA Medical Center Orlando, FL
Bryan Sakamoto, MD, PhD Staff Physician, Richard L. Roudebush VA Medical Center Assistant Professor of Clinical Anesthesia Indiana University School of Medicine Indianapolis, IN
Jack D. Wright, PharmD Chief of Pharmacy, Beckley VA Medical Center Beckley, WV
Sponsor
This roundtable discussion is sponsored by Heron Therapeutics.
This roundtable discussion is sponsored by Heron Therapeutics.
Sponsor
This roundtable discussion is sponsored by Heron Therapeutics.
Click here to read an edited transcript of a mult-disciplinary expert roundtable discussion in which surgeons, pharmacists, anesthesiologists and pain experts discuss insights and best practices for managing peri-operative pain and optimizing patient care.
Chad Brummett, MD Associate Professor, Anesthesiology, Director, Anesthesia Clinical Research, Director, Division of Pain Research, Michigan Medicine Back & Pain Center Ann Arbor, MI
PARTICIPANTS
Andrew C. Eppstein, MD Assistant Professor of Clinical Surgery, Indiana University School of Medicine Chief of General Surgery, Richard L. Roudebush VA Medical Center Indianapolis, IN
Nicholas Giori MD, PhD Professor of Orthopedic Surgery, Stanford University Chief of Orthopedic Surgery, VA Palo Alto Health Care System Palo Alto, CA
Georgine Lamvu, MD, MHP Professor in Obstetrics and Gynecology, University of Central Florida College of Medicine Division of Surgery, Gynecology Section Orlando VA Medical Center Orlando, FL
Bryan Sakamoto, MD, PhD Staff Physician, Richard L. Roudebush VA Medical Center Assistant Professor of Clinical Anesthesia Indiana University School of Medicine Indianapolis, IN
Jack D. Wright, PharmD Chief of Pharmacy, Beckley VA Medical Center Beckley, WV
Click here to read an edited transcript of a mult-disciplinary expert roundtable discussion in which surgeons, pharmacists, anesthesiologists and pain experts discuss insights and best practices for managing peri-operative pain and optimizing patient care.
Chad Brummett, MD Associate Professor, Anesthesiology, Director, Anesthesia Clinical Research, Director, Division of Pain Research, Michigan Medicine Back & Pain Center Ann Arbor, MI
PARTICIPANTS
Andrew C. Eppstein, MD Assistant Professor of Clinical Surgery, Indiana University School of Medicine Chief of General Surgery, Richard L. Roudebush VA Medical Center Indianapolis, IN
Nicholas Giori MD, PhD Professor of Orthopedic Surgery, Stanford University Chief of Orthopedic Surgery, VA Palo Alto Health Care System Palo Alto, CA
Georgine Lamvu, MD, MHP Professor in Obstetrics and Gynecology, University of Central Florida College of Medicine Division of Surgery, Gynecology Section Orlando VA Medical Center Orlando, FL
Bryan Sakamoto, MD, PhD Staff Physician, Richard L. Roudebush VA Medical Center Assistant Professor of Clinical Anesthesia Indiana University School of Medicine Indianapolis, IN
Jack D. Wright, PharmD Chief of Pharmacy, Beckley VA Medical Center Beckley, WV
A significant unmet need exists for users of acute medications for the treatment of migraine attacks. These medications can be ineffective or associated with undesirable side effects. However, a novel unique therapy, ubrogepant, has demonstrated efficacy for the acute treatment of migraine.
1. Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine
Audio file
2. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine
Audio file
3. Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine
Audio file
Podcast References
1. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496-505.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858.
3. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401.
4. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012;6(3):124-32.
5. Minen M, Shome A, Halpern A, Tishler L, Brennan KC, Loder E, et al. A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache. 2016;56(4):725-40.
6. Becker WJ. Acute migraine treatment in adults. Headache. 2015;55(6):778-93.
7. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.
8. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821-8.
9. Messali AJ, Yang M, Gillard P, Tsai K, Tepper SJ, Bloudek LM, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54(7):1120-30.
10. Katic BJ, Rajagopalan S, Ho TW, Chen YT, Hu XH. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500.
11. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543-59.
12. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573-82.
Sponsor
This supplement was sponsored by Allergan plc, with medical writing and editori…
This supplement was sponsored by Allergan plc, with medical writing and editori…
Sponsor
This supplement was sponsored by Allergan plc, with medical writing and editori…
A significant unmet need exists for users of acute medications for the treatment of migraine attacks. These medications can be ineffective or associated with undesirable side effects. However, a novel unique therapy, ubrogepant, has demonstrated efficacy for the acute treatment of migraine.
1. Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine
Audio file
2. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine
Audio file
3. Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine
Audio file
Podcast References
1. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496-505.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858.
3. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401.
4. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012;6(3):124-32.
5. Minen M, Shome A, Halpern A, Tishler L, Brennan KC, Loder E, et al. A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache. 2016;56(4):725-40.
6. Becker WJ. Acute migraine treatment in adults. Headache. 2015;55(6):778-93.
7. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.
8. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821-8.
9. Messali AJ, Yang M, Gillard P, Tsai K, Tepper SJ, Bloudek LM, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54(7):1120-30.
10. Katic BJ, Rajagopalan S, Ho TW, Chen YT, Hu XH. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500.
11. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543-59.
12. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573-82.
A significant unmet need exists for users of acute medications for the treatment of migraine attacks. These medications can be ineffective or associated with undesirable side effects. However, a novel unique therapy, ubrogepant, has demonstrated efficacy for the acute treatment of migraine.
1. Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine
Audio file
2. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine
Audio file
3. Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine
Audio file
Podcast References
1. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496-505.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858.
3. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010;9(4):391-401.
4. Ahmed F. Headache disorders: differentiating and managing the common subtypes. Br J Pain. 2012;6(3):124-32.
5. Minen M, Shome A, Halpern A, Tishler L, Brennan KC, Loder E, et al. A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache. 2016;56(4):725-40.
6. Becker WJ. Acute migraine treatment in adults. Headache. 2015;55(6):778-93.
7. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20.
8. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821-8.
9. Messali AJ, Yang M, Gillard P, Tsai K, Tepper SJ, Bloudek LM, et al. Treatment persistence and switching in triptan users: a systematic literature review. Headache. 2014;54(7):1120-30.
10. Katic BJ, Rajagopalan S, Ho TW, Chen YT, Hu XH. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500.
11. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543-59.
12. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573-82.
The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.
This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.
The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.
This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.
The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.
This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.
The ideas and opinions expressed in Best of 2019 – The RA Report: Top News Highlights do not necessarily reflect those of the publisher. Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
The ideas and opinions expressed in Best of 2019 – The RA Report: Top News Highlights do not necessarily reflect those of the publisher. Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
The ideas and opinions expressed in Best of 2019 – The RA Report: Top News Highlights do not necessarily reflect those of the publisher. Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
Claudia A. Chiriboga, MD, MPH, FAAN (Program Chair) Professor of Neurology and Pediatrics at CUIMC Division of Pediatric Neurology Columbia University Irving Medical Center New York, NY
Diana P. Castro, MD Assistant Professor Pediatrics and Neurology Neurotherapeutics UT Southwestern Medical Center Neurologist Children’s Health Dallas, TX
Mary Schroth, MD Chief Medical Officer Cure SMA Elk Grove Village, IL
Charlotte J. Sumner, MD Professor of Neurology and Neuroscience Johns Hopkins University School of Medicine Baltimore, MD
Kathryn J. Swoboda, MD Katherine B. Sims, MD, Endowed Chair in Neurogenetics Director, Neurogenetics Program Mass General Hospital for Children Boston, MA
Sponsor
This supplement is sponsored by Genentech, a member of the Roche Group.
Claudia A. Chiriboga, MD, MPH, FAAN (Program Chair) Professor of Neurology and Pediatrics at CUIMC Division of Pediatric Neurology Columbia University Irving Medical Center New York, NY
Diana P. Castro, MD Assistant Professor Pediatrics and Neurology Neurotherapeutics UT Southwestern Medical Center Neurologist Children’s Health Dallas, TX
Mary Schroth, MD Chief Medical Officer Cure SMA Elk Grove Village, IL
Charlotte J. Sumner, MD Professor of Neurology and Neuroscience Johns Hopkins University School of Medicine Baltimore, MD
Kathryn J. Swoboda, MD Katherine B. Sims, MD, Endowed Chair in Neurogenetics Director, Neurogenetics Program Mass General Hospital for Children Boston, MA
How prepared are you to recognize and meet the needs of patients with spinal muscular atrophy?
Learn more about spinal muscular atrophy in this supplement to Pediatric News.
Claudia A. Chiriboga, MD, MPH, FAAN (Program Chair) Professor of Neurology and Pediatrics at CUIMC Division of Pediatric Neurology Columbia University Irving Medical Center New York, NY
Diana P. Castro, MD Assistant Professor Pediatrics and Neurology Neurotherapeutics UT Southwestern Medical Center Neurologist Children’s Health Dallas, TX
Mary Schroth, MD Chief Medical Officer Cure SMA Elk Grove Village, IL
Charlotte J. Sumner, MD Professor of Neurology and Neuroscience Johns Hopkins University School of Medicine Baltimore, MD
Kathryn J. Swoboda, MD Katherine B. Sims, MD, Endowed Chair in Neurogenetics Director, Neurogenetics Program Mass General Hospital for Children Boston, MA
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Sponsor
This supplement was sponsored by Primary Care Education Consortium and Primary …
Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
Reducing Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
This supplement offers the opportunity to earn a total of 1 CME credit.
Credit is awarded for successful completion of the online evaluation at the link below. This link may also be found within the supplement on the first page of the article.
To receive CME credit, please read the journal article and, upon completion, go to www.pceconsortium.org/CVEvents to complete the online post-test and receive your certificate of credit.
